The head of the EMA has reiterated that there is no evidence to limit the use of AstraZeneca's COVID-19 vaccine in any age group, after Germany and Canada imposed restrictions in younger pa
In the latest episode of the pharmaphorum podcast Dominic Tyer speaks with GlaxoSmithKline’s Philip Cruz about the discovery and commercialisation of new vaccines in the light of the pandem
Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week.
The EU looks set to approve emergency use of a third antibody therapy for COVID-19 after its human medicines committee backed use of Celltrion's regdanvimab at its March meeting. <